Covid-19: Bangladesh to receive over 14.5 million vaccine by next month which includes 6 million Pfizer, 3 million Moderna and 2.9 million Astrazeneca
- Thread starter Black_cats
- Start date
Black_cats
ELITE MEMBER
- Joined
- Dec 31, 2010
- Messages
- 10,031
- Reaction score
- -5
LOL. If you want to analyze some thing, do it correctly, are you educated in UK ?
You cannot make the analyze like that since only 5 % of Indonesian is fully vaccinated. This will be different if you compare to US and UK where already huge portion are vaccinated. You cannot compare these to deduct conclusion on which vaccines is more effective since the situation is different.
Those even in Kudus region with Delta variants, most health workers are still only getting first dose, not yet second dose as data reveal the anti body increase significantly in the second dose.
The data about Delta varian can be seen in this
As of June 17, 6,085 health workers and health support personnel in Kudus had been vaccinated with the first dose, and 5,888 people had received the second dose.
“Almost 100 percent of the health workers in Kudus, amounting to around 6,000 people, have received the first and second doses of vaccination," Badai said.
"Of this number, only 308 health workers were exposed or around 5.1 percent of the total number of health workers. Most of them have recovered and have started working again," he said.
Abdul Aziz Achyar, the director of Kudus's dr. Loekmono Hadi Regional General Hospital, said a total of 153 health workers at the hospital confirmed to have Covid-19. Only 11 people, or 7.1 percent, needed hospitalization. The other 86 (56 percent) used to be in self-isolation but now ready to work, following the rest of their colleagues who had recovered earlier.
Sinovac Vaccine Protects Health Workers From Severe Covid-19 in Delta-Hit Kudus
Most of the 308 health workers vaccinated with Sinovac's Coronavac vaccine in Kudus recovered from the disease last week.jakartaglobe.id
While this is a data for health workers for any Covid cases
The number of Covid-19 deaths among health workers in the study
Source: Health Ministry
Groups Deaths Total % Not vaccinated 17 28,055 0.66 Vaccinated with the first dose 3 8,458 0.03 Vaccinated with the second dose 1 91,777 0.001
The number of Covid-19 hospitalization among health workers in the study
Source: Health Ministry
Groups Hospitalization Total % Not vaccinated 102 28,055 0.36 Vaccinated with the first dose 24 8,458 0.20 Vaccinated with the second dose 7 91,777 0.007
The number of Covid-19 infection among health workers in the study
Groups Infected Total % Not vaccinated 2,431 28,055 8.66 Vaccinated with the first dose 657 8,458 7.76 Vaccinated with the second dose 521 91,777 0.56
Indonesia Says Sinovac's Vaccine 98% Effective to Prevent Deaths From Covid-19
Sinovac's vaccine has been 98 percent effective in reducing the number of deaths due to Covid-19 among health workers in Jakarta.jakartaglobe.id
What @UKBengali has said that has some valid point as pointed by Wall Street Journal. Both Thailand and Indonesia has signaled of using booster doses to the health care workers who have taken two shots of Chinese vaccine.
Countries Signal Doubts About Delta Protection From Chinese Vaccine
Thailand and Indonesia say they will give a booster shot to healthcare workers who received Sinovac
More than 677,000 healthcare workers in Thailand have received China’s Sinovac vaccine.
PHOTO: CHAIWAT SUBPRASOM/ZUMA PRESS
By
Feliz Solomon and
Chao Deng
July 13, 2021 9:45 am ET
Thailand became the latest country to signal waning confidence in a Chinese vaccine against the highly contagious Delta variant, saying it would offer booster shots of Western doses to healthcare workers.
Healthcare workers who received two doses of the vaccine developed by Sinovac Biotech Ltd. would be given a third shot made by either Pfizer Inc. andBioNTech SE or AstraZeneca PLC, Thailand’s health ministry said Monday. Those who had only one dose would receive AstraZeneca as their second.
The decision to mix the vaccines makes Thailand the latest country to show reservations about whether Chinese vaccines work well enough to protect medical workers against the Delta variant, which was first detected in India and is thought to be far more contagious than earlier versions of the virus. The strain has spread to at least 98 countries.
Indonesia said last week that it would offer medical workers a booster shot from Moderna Inc. Around 90% of the country’s medical staff have received two doses of the Sinovac vaccine, but hundreds have fallen ill from Covid-19, reducing medical manpower amid a surge of the virus, according to Indonesia’s health ministry and doctors’ groups.
Sinovac didn’t respond to a request for comment.
The Persian Gulf island nation of Bahrain said in June that it had started giving booster shots of the Pfizer vaccine to vulnerable residents who had received two shots of a separate Chinese vaccine made by Sinopharm.
Sinovac and Sinopharm are studying the protection the vaccines provide against the Delta variant, but haven’t released any data yet. Both companies have said a booster shot may be needed at some point after their two-dose regimens.
Two recent studies in the U.K. determined that vaccines made by Pfizer and AstraZeneca are highly effective at preventing severe illness caused by the variant, while their overall protection against infection may be reduced. A separate study of the Pfizer vaccine conducted in Israel showed similar outcomes.
A Thai health worker receiving the Sinovac vaccine.
PHOTO: ATHIT PERAWONGMETHA/REUTERS
The Chinese vaccines have been central to inoculation efforts in many countries throughout the developing world. Sinopharm and Sinovac have agreed to provide 550 million doses to be distributed through the United Nations-backed Covax Facility, an initiative aiming to provide vaccines to the world’s most vulnerable. The promised doses make up a significant share of the two billion that Covax plans to deliver by early 2022, with some 110 million doses of the Chinese vaccines to be delivered immediately.
Both Sinovac and Sinopharm’s vaccines have been granted emergency use approval by the World Health Organization. A spokesman for WHO said that while the efficacy of Sinovac’s vaccine was lower than that of others approved by the health body, efficacy across vaccines was much higher against severe cases of Covid-19.
“As the severity of the infection decreases, so too does the efficacy of the vaccine,” the spokesman said. He added that all vaccines approved by WHO are “highly effective in preventing severe disease and hospitalization due to Covid-19.”
But Thailand’s shift in strategy reflects growing public skepticism over whether the vaccines are good enough for healthcare workers, whose work makes them more susceptible to infection. The decision followed public outcry over the death of a nurse last week and the subsequent disclosure by health authorities that hundreds of healthcare workers were infected between April and July.
Officials stressed that the number of infections, 618, represented less than 0.1% of the more than 677,000 healthcare workers who received two doses of Sinovac. Of those, only two fell seriously ill—the nurse who died and another currently in critical condition.
Authorities are still investigating the nurse’s death. According to Sophon Iamsirithaworn, deputy director general of Thailand’s Department of Disease Control, the woman was 30 years old and suffered from obesity, a high-risk factor.
Companies are working on coronavirus booster shots, as some early studies suggest antibody levels against Covid-19 wane with time, making boosters more necessary. We explore what that means for individual consumers. Illustration:
Laura Kammermann/The Wall Street JournalTHE WALL STREET JOURNAL INTERACTIVE EDITION
“We’d like to emphasize that despite this, all vaccines have been proven to be efficient in preventing hospitalization and death,” Pensom Lertsithichai, an official with Thailand’s Ministry of Foreign Affairs, said at a press briefing on Monday.
The nurse’s death nonetheless worried many Thais and prompted calls for shots with demonstrably higher efficacy. Some vented anger online and joined social media campaigns calling for Thailand to import mRNA vaccines, such as those made by Pfizer and Moderna.
Thailand’s vaccine plan is largely reliant on shots developed by AstraZeneca, which joined with a local manufacturer that only recently began delivering doses. Most of the country’s healthcare workers were vaccinated with Sinovac before the AstraZeneca doses became available.
About 4.7% of Thailand’s 69 million people are fully vaccinated, according to Our World in Data. About 97% of the country’s healthcare workers are inoculated, while 15% of people aged 60 or over and 18% of those with underlying illness have received at least one dose.
The country is in the midst of its third and worst wave of infections. To date, Thailand has recorded more than 350,000 cases and 2,847 deaths. While cases stayed low through most of last year, they rose rapidly in recent months and now regularly reach several thousand each day. Officials said the Alpha variant, first detected in the U.K., was still the country’s dominant strain as of early July, but the Delta variant had overtaken it in the capital, Bangkok, and could soon eclipse it nationwide.
Indonesia, which has vaccinated about 5.5% of its 270 million people, is facing a massive wave of infections driven by the Delta variant that has seen caseloads and deaths reach new highs.
“Our health workers are under extraordinary pressure, especially in this second wave of the pandemic, so we want to confirm they are maximally protected,” Indonesian Health Minister Budi Gunadi Sadikin said on Sunday, when three million donated doses of the vaccine arrived from the U.S.
At least 20 Indonesian doctors who were fully vaccinated with Sinovac died from Covid-19 between February and June, according to the Indonesian Medical Association’s Covid-19 mitigation group. At least 10 of 48 doctors who died from Covid-19 last month were also fully vaccinated with Sinovac shots, the group said.
—Jon Emont and Wilawan Watcharasakwet contributed to this article.
Write to Feliz Solomon at feliz.solomon@wsj.comand Chao Deng at Chao.Deng@wsj.com
Indos
PDF THINK TANK: ANALYST
- Joined
- Jul 25, 2013
- Messages
- 23,466
- Reaction score
- 24
- Country
- Location
What @UKBengali has said that has some valid point as pointed by Wall Street Journal. Both Thailand and Indonesia has signaled of using booster doses to the health care workers who have taken two shots of Chinese vaccine.
Countries Signal Doubts About Delta Protection From Chinese Vaccine
Thailand and Indonesia say they will give a booster shot to healthcare workers who received Sinovac
More than 677,000 healthcare workers in Thailand have received China’s Sinovac vaccine.
PHOTO: CHAIWAT SUBPRASOM/ZUMA PRESS
By
Feliz Solomon and
Chao Deng
July 13, 2021 9:45 am ET
Thailand became the latest country to signal waning confidence in a Chinese vaccine against the highly contagious Delta variant, saying it would offer booster shots of Western doses to healthcare workers.
Healthcare workers who received two doses of the vaccine developed by Sinovac Biotech Ltd. would be given a third shot made by either Pfizer Inc. andBioNTech SE or AstraZeneca PLC, Thailand’s health ministry said Monday. Those who had only one dose would receive AstraZeneca as their second.
The decision to mix the vaccines makes Thailand the latest country to show reservations about whether Chinese vaccines work well enough to protect medical workers against the Delta variant, which was first detected in India and is thought to be far more contagious than earlier versions of the virus. The strain has spread to at least 98 countries.
Indonesia said last week that it would offer medical workers a booster shot from Moderna Inc. Around 90% of the country’s medical staff have received two doses of the Sinovac vaccine, but hundreds have fallen ill from Covid-19, reducing medical manpower amid a surge of the virus, according to Indonesia’s health ministry and doctors’ groups.
Sinovac didn’t respond to a request for comment.
The Persian Gulf island nation of Bahrain said in June that it had started giving booster shots of the Pfizer vaccine to vulnerable residents who had received two shots of a separate Chinese vaccine made by Sinopharm.
Sinovac and Sinopharm are studying the protection the vaccines provide against the Delta variant, but haven’t released any data yet. Both companies have said a booster shot may be needed at some point after their two-dose regimens.
Two recent studies in the U.K. determined that vaccines made by Pfizer and AstraZeneca are highly effective at preventing severe illness caused by the variant, while their overall protection against infection may be reduced. A separate study of the Pfizer vaccine conducted in Israel showed similar outcomes.
A Thai health worker receiving the Sinovac vaccine.
PHOTO: ATHIT PERAWONGMETHA/REUTERS
The Chinese vaccines have been central to inoculation efforts in many countries throughout the developing world. Sinopharm and Sinovac have agreed to provide 550 million doses to be distributed through the United Nations-backed Covax Facility, an initiative aiming to provide vaccines to the world’s most vulnerable. The promised doses make up a significant share of the two billion that Covax plans to deliver by early 2022, with some 110 million doses of the Chinese vaccines to be delivered immediately.
Both Sinovac and Sinopharm’s vaccines have been granted emergency use approval by the World Health Organization. A spokesman for WHO said that while the efficacy of Sinovac’s vaccine was lower than that of others approved by the health body, efficacy across vaccines was much higher against severe cases of Covid-19.
“As the severity of the infection decreases, so too does the efficacy of the vaccine,” the spokesman said. He added that all vaccines approved by WHO are “highly effective in preventing severe disease and hospitalization due to Covid-19.”
But Thailand’s shift in strategy reflects growing public skepticism over whether the vaccines are good enough for healthcare workers, whose work makes them more susceptible to infection. The decision followed public outcry over the death of a nurse last week and the subsequent disclosure by health authorities that hundreds of healthcare workers were infected between April and July.
Officials stressed that the number of infections, 618, represented less than 0.1% of the more than 677,000 healthcare workers who received two doses of Sinovac. Of those, only two fell seriously ill—the nurse who died and another currently in critical condition.
Authorities are still investigating the nurse’s death. According to Sophon Iamsirithaworn, deputy director general of Thailand’s Department of Disease Control, the woman was 30 years old and suffered from obesity, a high-risk factor.
Companies are working on coronavirus booster shots, as some early studies suggest antibody levels against Covid-19 wane with time, making boosters more necessary. We explore what that means for individual consumers. Illustration:
Laura Kammermann/The Wall Street JournalTHE WALL STREET JOURNAL INTERACTIVE EDITION
“We’d like to emphasize that despite this, all vaccines have been proven to be efficient in preventing hospitalization and death,” Pensom Lertsithichai, an official with Thailand’s Ministry of Foreign Affairs, said at a press briefing on Monday.
The nurse’s death nonetheless worried many Thais and prompted calls for shots with demonstrably higher efficacy. Some vented anger online and joined social media campaigns calling for Thailand to import mRNA vaccines, such as those made by Pfizer and Moderna.
Thailand’s vaccine plan is largely reliant on shots developed by AstraZeneca, which joined with a local manufacturer that only recently began delivering doses. Most of the country’s healthcare workers were vaccinated with Sinovac before the AstraZeneca doses became available.
About 4.7% of Thailand’s 69 million people are fully vaccinated, according to Our World in Data. About 97% of the country’s healthcare workers are inoculated, while 15% of people aged 60 or over and 18% of those with underlying illness have received at least one dose.
The country is in the midst of its third and worst wave of infections. To date, Thailand has recorded more than 350,000 cases and 2,847 deaths. While cases stayed low through most of last year, they rose rapidly in recent months and now regularly reach several thousand each day. Officials said the Alpha variant, first detected in the U.K., was still the country’s dominant strain as of early July, but the Delta variant had overtaken it in the capital, Bangkok, and could soon eclipse it nationwide.
Indonesia, which has vaccinated about 5.5% of its 270 million people, is facing a massive wave of infections driven by the Delta variant that has seen caseloads and deaths reach new highs.
“Our health workers are under extraordinary pressure, especially in this second wave of the pandemic, so we want to confirm they are maximally protected,” Indonesian Health Minister Budi Gunadi Sadikin said on Sunday, when three million donated doses of the vaccine arrived from the U.S.
At least 20 Indonesian doctors who were fully vaccinated with Sinovac died from Covid-19 between February and June, according to the Indonesian Medical Association’s Covid-19 mitigation group. At least 10 of 48 doctors who died from Covid-19 last month were also fully vaccinated with Sinovac shots, the group said.
—Jon Emont and Wilawan Watcharasakwet contributed to this article.
Write to Feliz Solomon at feliz.solomon@wsj.comand Chao Deng at Chao.Deng@wsj.com
Getting the booster doesnt mean Sinovac is not effective, it is to give more protection for health workers, nothing wrong about it. And since most doctors get them early this year so we need to give booster in late year because the pandemic will likely continue until 2022. Second booster for health worker have been discussed, not only Indonesia and Thailand but others, even US.
Dont highligh 20 doctors who died, all vaccine cannot give 100 % protection. Sinovac is 98 % effective to prevent death base on Indonesian real data, just look on data I have given in previous post, That is data, not unfair opinion by using 20 death workers without giving total number of health workers like this publication reported
In February it is still early vaccination program, even until Today many health workers havent got second jobs yet. We dont give third booster during this period, but later for some health workers who have already gotten Sinovacs in early this year, it is because Sinovac only give protection around 1 year.
Believe data, not opinion from journalist.
Black_cats
ELITE MEMBER
- Joined
- Dec 31, 2010
- Messages
- 10,031
- Reaction score
- -5
Booster is not just the issue. Thailand is stopping second vaccination with Chinese one those who got just 1 shot and booster shot for those who got 2 shots already.
Same is happening in Bahrain. Indonesia is basically doing the same as well. All those are primarily because there are doubts on efficiency of Chinese vaccine not because it’s 6 month and they need a booster dose as you are trying to say.
Indos
PDF THINK TANK: ANALYST
- Joined
- Jul 25, 2013
- Messages
- 23,466
- Reaction score
- 24
- Country
- Location
Talking about effectiveness, we need to see the data. Data has been given by Indonesian Government. That is not just mulling and opinion. The data about Delta variant hasnt been comprehensive yet, but at least we can see the statistic in Kudus region and there is data you can read on my previous post.
For Indonesia, if we can protect our health workers better, so why not ? Since they are our backbone in handling this pandemic. We give them salary incentive and now this ones. Just wait some time before making an assumption, so far the data in Kudus region is the strongest if we compare with just concern and opinions.
Thailand and Bahrain should also release the data if they feel unsafe using Chinese vaccine, and so far they dont back it with data. So look like it is just an emotional concern, not scientific. And how about what is happening in India who get Astra Zenika, we should compare data to see whether China vaccine is really much less effective like what Western media like to say.
EasyNow
SENIOR MEMBER
- Joined
- Oct 11, 2013
- Messages
- 2,015
- Reaction score
- -3
- Country
- Location
Maybe that's because the true supa pawa failed to deliver the vaccine as agreed? Your credibility as a reliable manufacturer is shot to smithereens.
Bilal9
ELITE MEMBER
- Joined
- Feb 4, 2014
- Messages
- 26,569
- Reaction score
- 9
- Country
- Location
I cannot believe that shameless dung-bathers like these have the gall to come in here and open their mouth when they are floating the Covid-dead down their own rivers for want of Chita-wood used in funeral pyres and people dying by the hundreds of thousands from mystery diseases completely different than Covid (from causes completely unknown). We have friends living in India who have reported this.
'Nobody knows': Experts baffled by mystery illness in India
NEW DELHI (AP) — Health officials and experts are still baffled by a mysterious illness that has left over 500 people hospitalized and one person dead in the southern Indian state of Andhra Pradesh.
apnews.com
Just a f*cked up situation created by a f*ck-up leader that they themselves elected.
Mahaan!
Protest_again
BANNED
- Joined
- May 19, 2019
- Messages
- 4,650
- Reaction score
- -60
- Country
- Location
Billi.. why are you hyper? Let's all wait and see how both our countries manage corona till the very end. Mutations are still on going. India is atleast is vaccinating its populace at a high rate through it's own manufacturing. And dumb idiots like you talk as if that Bango land has become a pharma hub on PDF with nothing to show for it. Lol. I mean vaccinating 25000 a day is shameful. India is vaccinating on an average 5 million a day. Yes, I have the gall to come and quote you numbers.I cannot believe that shameless dung-bathers like these have the gall to come in here and open their mouth when they are floating the Covid-dead down their own rivers for want of Chita-wood used in funeral pyres and people dying by the hundreds of thousands from mystery diseases completely different than Covid (from causes completely unknown). We have friends living in India who have reported this.
'Nobody knows': Experts baffled by mystery illness in India
NEW DELHI (AP) — Health officials and experts are still baffled by a mysterious illness that has left over 500 people hospitalized and one person dead in the southern Indian state of Andhra Pradesh.
Just a f*cked up situation created by a f*ck-up leader that they themselves elected.
Mahaan!
Corona is not going away anytime soon. Let's see how many waves both countries will go through before they are safer.
India has a tradition to of river burial. I know you idiots would not understand it.
Baby Leone
SENIOR MEMBER
- Joined
- Aug 25, 2011
- Messages
- 5,437
- Reaction score
- -2
- Country
- Location
what is ths ?
Bilal9
ELITE MEMBER
- Joined
- Feb 4, 2014
- Messages
- 26,569
- Reaction score
- 9
- Country
- Location
Yeah whatever.
BD has a CHOICE now on which vaccines to use.
There is no clear evidence on strong efficacy of Chinese vaccines but there is on Pfizer and AstraZeneca. In fact most of the evidence from numerous countries on real world data points the other way for Chinese vaccines.
UK data gives 95% protection on hospitalisation from the Indian Delta variant and 97-98% from death with both Pfizer and AstraZeneca 2 doses. UK data is probably the best as they have had a massive surge of the Indian Delta variant and are using both Pfizer and AstraZeneca in abundance.
The Indonesian poster is just emotionally wanting the Chinese vaccine to succeed as his country has mainly vaccinated with 50 million doses so far with the Chinese vaccines. You cannot blame him but he is not looking at this from a neutral perspective at all.
BD has a choice. It will get abundant supplies of Pfizer/Moderna and millions more to add to the AstraZeneca stock.
There are some logistical issues with Pfizer due to storage requirements but it makes total logical reasoning to target as much Pfizer/Moderna and AstraZeneca at the most "vulnerable" and use Sinopharm at the lesser "vulnerable". You want the most vulnerable to have proven vaccines without taking a chance with one without this proof.
This is the last I am saying on this matter as there is nothing to really argue with this line of logic. Absurd that this has somehow became a debating issue.
BD has a CHOICE now on which vaccines to use.
There is no clear evidence on strong efficacy of Chinese vaccines but there is on Pfizer and AstraZeneca. In fact most of the evidence from numerous countries on real world data points the other way for Chinese vaccines.
UK data gives 95% protection on hospitalisation from the Indian Delta variant and 97-98% from death with both Pfizer and AstraZeneca 2 doses. UK data is probably the best as they have had a massive surge of the Indian Delta variant and are using both Pfizer and AstraZeneca in abundance.
The Indonesian poster is just emotionally wanting the Chinese vaccine to succeed as his country has mainly vaccinated with 50 million doses so far with the Chinese vaccines. You cannot blame him but he is not looking at this from a neutral perspective at all.
BD has a choice. It will get abundant supplies of Pfizer/Moderna and millions more to add to the AstraZeneca stock.
There are some logistical issues with Pfizer due to storage requirements but it makes total logical reasoning to target as much Pfizer/Moderna and AstraZeneca at the most "vulnerable" and use Sinopharm at the lesser "vulnerable". You want the most vulnerable to have proven vaccines without taking a chance with one without this proof.
This is the last I am saying on this matter as there is nothing to really argue with this line of logic. Absurd that this has somehow became a debating issue.
Last edited:
Black_cats
ELITE MEMBER
- Joined
- Dec 31, 2010
- Messages
- 10,031
- Reaction score
- -5
July 21, 20214:54 AM EDTLast Updated 16 hours ago
Healthcare & Pharmaceuticals
Sinopharm's COVID-19 shot induces weaker antibody responses to Delta -study
Reuters
2 minute read
Signage of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 5, 2020. REUTERS/Tingshu Wang/File Photo
BEIJING, July 21 (Reuters) - Sinopharm's COVID-19 vaccine elicited weaker antibody responses against the Delta variant, based on the first published study of its effect against the more contagious version.
Antibody levels in people receiving Sinopharm's BBIBP-CorV vaccine had a 1.38-fold reduction to the Delta variant versus an older version of the coronavirus first identified in Wuhan, a lab study based on samples from people in Sri Lanka showed. https://bit.ly/3hTjzJt
The study was conducted by scientists from University of Sri Jayewardenepura as well as Colombo Municipal Council in Sri Lanka, and University of Oxford in the United Kingdom.
The Delta variant, first found in India late last year, has since become the dominant version of the virus worldwide and is behind a recent surge in infections reported in many countries including Britain, Indonesia, the United States and South Korea. It has been detected in more than 90 nations worldwide.
The vaccine from Sinopharm, formally China National Pharmaceutical Group, also showed a more pronounced 10-fold decrease in antibody levels to the Beta variant, first found in South Africa, the study, published on Monday ahead of peer review, showed.
Researchers said they found no significant difference in levels of antibodies to the two variants from blood serum of vaccinated people compared with the serum of those who had been naturally infected.
This suggested that Sinopharm's vaccine may be able to induce antibody-based responses against the two variants similar to the levels seen following natural infection, the paper said.
The two-dose vaccine is one of the most widely used COVID-19 shots in China, and Sinopharm agreed to provide up to 170 million doses to the global vaccine sharing scheme COVAX through to the middle of 2022. read more
Reporting by Roxanne Liu and Ryan Woo; Editing by Miyoung Kim and Jane Merriman
Our Standards: The Thomson Reuters Trust Principles.
Sinopharm's COVID-19 shot induces weaker antibody responses to Delta -study
Sinopharm's COVID-19 vaccine elicited weaker antibody responses against the Delta variant, based on the first published study of its effect against the more contagious version.
@UKBengali
Last edited:
Indos
PDF THINK TANK: ANALYST
- Joined
- Jul 25, 2013
- Messages
- 23,466
- Reaction score
- 24
- Country
- Location
July 21, 20214:54 AM EDTLast Updated 16 hours ago
Healthcare & Pharmaceuticals
Sinopharm's COVID-19 shot induces weaker antibody responses to Delta -study
Reuters
2 minute read
Signage of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 5, 2020. REUTERS/Tingshu Wang/File Photo
BEIJING, July 21 (Reuters) - Sinopharm's COVID-19 vaccine elicited weaker antibody responses against the Delta variant, based on the first published study of its effect against the more contagious version.
Antibody levels in people receiving Sinopharm's BBIBP-CorV vaccine had a 1.38-fold reduction to the Delta variant versus an older version of the coronavirus first identified in Wuhan, a lab study based on samples from people in Sri Lanka showed. https://bit.ly/3hTjzJt
The study was conducted by scientists from University of Sri Jayewardenepura as well as Colombo Municipal Council in Sri Lanka, and University of Oxford in the United Kingdom.
The Delta variant, first found in India late last year, has since become the dominant version of the virus worldwide and is behind a recent surge in infections reported in many countries including Britain, Indonesia, the United States and South Korea. It has been detected in more than 90 nations worldwide.
The vaccine from Sinopharm, formally China National Pharmaceutical Group, also showed a more pronounced 10-fold decrease in antibody levels to the Beta variant, first found in South Africa, the study, published on Monday ahead of peer review, showed.
Researchers said they found no significant difference in levels of antibodies to the two variants from blood serum of vaccinated people compared with the serum of those who had been naturally infected.
This suggested that Sinopharm's vaccine may be able to induce antibody-based responses against the two variants similar to the levels seen following natural infection, the paper said.
The two-dose vaccine is one of the most widely used COVID-19 shots in China, and Sinopharm agreed to provide up to 170 million doses to the global vaccine sharing scheme COVAX through to the middle of 2022. read more
Reporting by Roxanne Liu and Ryan Woo; Editing by Miyoung Kim and Jane Merriman
Our Standards: The Thomson Reuters Trust Principles.
Sinopharm's COVID-19 shot induces weaker antibody responses to Delta -study
Sinopharm's COVID-19 vaccine elicited weaker antibody responses against the Delta variant, based on the first published study of its effect against the more contagious version.www.reuters.com
@UKBengali
Do they also conduct similar research on other vaccine ? Look like it is just focusing on Sinoparm......I mean how other vaccine performance when they deal with Delta varian ?
Similar threads
